Long-term effects of weight-reducing drugs in hypertensive patients (Q24239850)

1

0 references

Karl Horvath

2

0 references

Klaus Jeitler

3

0 references

Andrea Berghold

4

0 references

Anne K Stich

5

0 references

Eva Matyas

6

0 references

Nicole Pignitter

7

0 references

Ulrich Siering

Cochrane Database of Systematic Reviews

8

0 references

publication date

8 July 2009

0 references

published in

0 references

cites work

Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Safety and efficacy of sibutramine in overweight Hispanic patients with hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of sibutramine on abdominal fat mass, insulin resistance and blood pressure in obese hypertensive patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of sibutramine on the treatment of obesity in patients with arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of orlistat on obesity-related diseases - a six-month randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Efficacy and safety of sibutramine in obese white and African American patients with hypertension: a 1-year, double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Principles for enhanced recruitment of subjects in a large clinical trial. the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Absence of cardiac valve dysfunction in obese patients treated with sibutramine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Sibutramine produces dose-related weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of sibutramine on body weight and serum lipids: a double-blind, randomized, placebo-controlled study in 322 overweight and obese patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Cholesterol lowering effect of dietary weight loss and orlistat treatment--efficacy and limitations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Weight reduction by sibutramine in obese subjects in primary care medicine: the SAT Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Endocannabinoid blockade for improving glycemic control and lipids in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Sibutramine improves insulin sensitivity without alteration of serum adiponectin in obese subjects with Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effect of sibutramine on weight maintenance after weight loss: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Clinical efficacy of orlistat therapy in overweight and obese patients with insulin-treated type 2 diabetes: A 1-year randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

A randomized trial of sibutramine in the management of obese type 2 diabetic patients treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Decreasing levels of tumour necrosis factor alpha and interleukin 6 during lowering of body mass index with orlistat or placebo in obese subjects with cardiovascular risk factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effect of orlistat on cardiovascular disease risk in obese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Sibutramine enhances insulin sensitivity ameliorating metabolic parameters in a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Long-term effect of CB1 blockade with rimonabant on cardiometabolic risk factors: two year results from the RIO-Europe Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Long-term weight loss with sibutramine: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of sibutramine on ventricular dimensions and heart valves in obese patients during weight reduction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of weight loss in overweight/obese individuals and long-term hypertension outcomes: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

2007 Guidelines for the Management of Arterial Hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Long-term effects of weight-reducing interventions in hypertensive patients: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effect of sibutramine on weight loss and blood pressure: a meta-analysis of controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Drug treatments for obesity: orlistat, sibutramine, and rimonabant.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Blood pressure changes associated with sibutramine and weight management - an analysis from the 6-week lead-in period of the sibutramine cardiovascular outcomes trial (SCOUT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

Orlistat in the long-term treatment of obesity in primary care settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

One-year treatment of obesity: a randomized, double-blind, placebo-controlled, multicentre study of orlistat, a gastrointestinal lipase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

Second phase of a double-blind study clinical trial on Sibutramine for the treatment of patients suffering essential obesity: 6 months after treatment cross-over

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

Effects of equal weight loss with orlistat and placebo on body fat and serum fatty acid composition and insulin resistance in obese women

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021

Treatment with orlistat reduces cardiovascular risk in obese patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD007654.PUB2

7 January 2021